ArticleAsian Pacific journal of cancer prevention : APJCP2025
Circulating miR-6165 and miR-182-3p as Non-Invasive Biomarkers for Early Detection of Breast Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is one of the most prevalent malignancies and a significant cause of cancer-related mortality among women. Identifying reliable biomarkers for early detection and monitoring is crucial for improving patient outcomes. Therefore, we evaluated circulating miR-6165 and miR-182-3p expression levels in breast cancer patients and explored their potential as biomarkers.
methodsPlasma samples were collected from diagnosed breast cancer patients and healthy control subjects. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to assess the expression levels of miR-6165 and miR-182-3p. The data were analyzed using GraphPad Prism software (GraphPad Software, USA), and P-values at p < 0.05 were considered significant.
resultsOur findings show that both miR-6165 and miR-182-3p are significantly up-regulated in breast cancer patients compared to healthy controls (p < 0.05). These findings were conducted with 50 patients and 50 healthy individuals and were not significant in the age group under 40 years but were substantial between 40 and 60 years (p < 0.05) and over 60 years (p < 0.01). This positive regulation highlights their potential role in diagnosis and monitoring of the disease. A sensitivity of 85% and specificity of 90% were observed for miR-6165, and a sensitivity of 80% and specificity of 88% for miR-182-3p. Furthermore, we provided an analysis of the targets of miR-6165 and miR-182-3p, along with the associated genes, to indicate the underlying mechanisms involved in breast cancer progression. These potential targets as therapeutic biomarkers, may provide overcome the challenges of tumor resistance, and a valuable impact on future research.
conclusionThe elevated levels of circulating miR-6165 and miR-182-3p in breast cancer patients suggest their utility as promising non-invasive biomarkers for early detection and monitoring of breast cancer. Further validation studies are warranted to establish their clinical relevance and to explore their functional roles in breast cancer biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.